Hospital Beatriz Angelo — Clinical Trial Site

26 Registered trials

2 Currently recruiting

Organisation

Hospital Beatriz Angelo

Location

Loures, Portugal

Identifier

ORG-100041792

Address

Avenida Carlos Teixeira No 3, 2674-514, Portugal

Departments

#3001: Serviço de Oncologia
#5704: Serviço Neurologia
1807: Serviço Neurologia
2702: Serviço Neurologia
Gastroenterology
Ginecology
Medical Oncology
N/A
NA
Nefrology
Nephrology
Neurologia - HBA
Oncologia
Oncology
Psychiatry
PT10002: Serviço de Gastrenterologia
Serviço de Neurologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Psiquiatria

Clinical trials at this site (26)

Search interface

A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Ulcerative Colitis is a type of inflammatory bowel dise 4 2026-01-26
A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting

2025-522026-13-00 Obsessive compulsive disorder 4 2026-01-12
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended

2024-514891-41-00 HR+, HER2- advanced or metastatic breast cancer 6 2022-07-19
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended

2023-506518-33-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2021-11-10
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Muscle Invasive Bladder Cancer 11 2020-03-17
A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap… Ended

2022-501531-16-00 esophageal carcinoma 5 2020-01-24
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended

2023-509923-42-00 HER2- positive breast cancer 4 2017-07-06
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 5 2022-11-03
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended

2023-508828-35-01 Patients with advanced hormone receptor-positive/HER2- 5 2022-03-28
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv… Ended

2023-507493-41-00 relapsing multiple sclerosis (RMS) 5 2020-08-04
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Focal segmental glomerulosclerosis (FSGS) 5 2018-10-15